ASGARD THERAPEUTICS
Asgard Therapeutics is a private biotech company exploring the application of direct cell reprogramming technologies for cancer immunotherapies. Formed as a spin-off from Lund University, the Company is pioneering a gene therapy approach based on its proprietary TrojanDC technology, designed to set in motion immune responses based on the biological properties of professional antigen-presenting cells.
ASGARD THERAPEUTICS
Industry:
Biotechnology Therapeutics
Founded:
2018-01-01
Address:
Lund, Skane Lan, Sweden
Country:
Sweden
Website Url:
http://www.asgardthx.com
Total Employee:
1+
Status:
Active
Total Funding:
36 M EUR
Technology used in webpage:
Euro Gravity Forms Swedish Server Location
Similar Organizations
CSAVM - Union Chamber of Algae and Marine Plants
CSAVM - Union Chamber of Algae and Marine Plants is a Biotechnology Company.
Cygnal Therapeutics
Cygnal Therapeutics is a biotechnology company
IDAC Theranostics
IDAC Theranostics is a Biotechnology Company.
Isarna Therapeutics
Isarna Therapeutics is a biotechnology company.
Neoplants
Neoplants is a Biotechnology Company.
Telum Therapeutics
Telum Therapeutics is a biotechnology company.
Tethis S.p.A
Tethis is a bio- and nanotechnology company.
Xios Therapeutics
Xios Therapeutics is a biotechnology company .
Current Advisors List
Board_member
Board_member
2021-11-01
Board_member
2021-11-01
Board_member
2021-11-01
Board_observer
2021-11-01
Current Employees Featured
Fábio Rosa Co-founder and Head of Research @ Asgard Therapeutics
Co-founder and Head of Research
Filipe Pereira Co-founder, Board Member and Head of Innovation @ Asgard Therapeutics
Co-founder, Board Member and Head of Innovation
2018-12-01
Lars Hedbys Chairman Of The Board @ Asgard Therapeutics
Chairman Of The Board
2021-01-01
Cristiana Pires Co-Founder and CEO @ Asgard Therapeutics
Co-Founder and CEO
Founder
Investors List
RV Invest
RV Invest investment in Series A - Asgard Therapeutics
Boehringer Ingelheim Venture Fund
Boehringer Ingelheim Venture Fund investment in Series A - Asgard Therapeutics
Industrifonden
Industrifonden investment in Series A - Asgard Therapeutics
Novo Holdings
Novo Holdings investment in Series A - Asgard Therapeutics
Johnson & Johnson Innovation – JJDC
Johnson & Johnson Innovation – JJDC investment in Series A - Asgard Therapeutics
Boehringer Ingelheim Venture Fund
Boehringer Ingelheim Venture Fund investment in Seed Round - Asgard Therapeutics
Novo Holdings
Novo Holdings investment in Seed Round - Asgard Therapeutics
Industrifonden
Industrifonden investment in Seed Round - Asgard Therapeutics
LU Innovation
LU Innovation investment in Venture Round - Asgard Therapeutics
Official Site Inspections
http://www.asgardthx.com
- Host name: website-proxy.ilait.se
- IP address: 185.15.121.100
- Location: Sweden
- Latitude: 59.3247
- Longitude: 18.056
- Timezone: Europe/Stockholm
Asgardthx.com lookup results from whois.namesrs.com server:
- Domain created: 5th-Jan-2019
- Domain updated: 21st-Nov-2024
- Domain expires: 5th-Jan-2026 0 Years, 357 Days left
- Website age: 6 Years, 8 Days
- Registrar Domain ID: 2349840392_DOMAIN_COM-VRSN
- Registrar Url: http://www.namesrs.com
- Registrar WHOIS Server: whois.namesrs.com
- Registrar Abuse Contact Email: abuse@namesrs.com
- Registrar Abuse Contact Phone: +46.313011220
- Name server:
- NS1.ILAIT.SE
- NS2.ILAIT.SE
- NS3.ILAIT.SE
- NS4.ILAIT.SE
More informations about "Asgard Therapeutics"
Asgard Therapeutics - Crunchbase Company Profile
Asgard Therapeutics may be growing as it has successfully secured significant funding in a Series A investment round. The company received $32 million in backing from notable investors including J&J, Novo, and Boehringer, …See details»
Asgard Therapeutics - LinkedIn
Asgard Therapeutics is a private biotech company exploring the application of direct cell reprogramming technologies for cancer immunotherapies.See details»
Asgard Therapeutics selects Exothera to bring their viral vector …
Jun 11, 2024 For more information, please visit: www.asgardthx.com About Exothera SA. Exothera is a contract, development, and manufacturing organization (CDMO) dedicated to …See details»
Eurostars-funded REPRINT consortium reaches milestones with …
Apr 11, 2023 cristiana.pires@asgardthx.com About Asgard Therapeutics ... Antineo is a French private Contract Research Organization specializing in Preclinical Oncology. Antineo …See details»
Asgard Therapeutics AB - Privacy Policy - Asgard Therapeutics
We may also collect your personal data from a third party, usually from the company or organization you represent. 3. How we process your personal data ...See details»
Asgard Therapeutics Company Profile 2024: Valuation, Funding ...
Information on valuation, funding, cap tables, investors, and executives for Asgard Therapeutics. Use the PitchBook Platform to explore the full profile.See details»
Asgard Therapeutics - Facebook
Asgard Therapeutics. 91 likes. Spin-off company from the Cell Reprogramming Lab at Lund University focusing on developing cancer immunotherapies based on...See details»
Asgard Therapeutics - VentureRadar
"Asgard Therapeutics is a biotech company that pioneers in vivo direct cell reprogramming for cancer immunotherapy. It aims to develop its lead program AT-108, a first-in-class gene …See details»
Asgard - The Index Project
Asgard Therapeutic’s mission is to pioneer direct cell reprogramming for cancer immunotherapy. Our current focus is to develop scalable reprogramming technologies enabling the direct in …See details»
Asgard Therapeutics - Craft
Asgard Therapeutics has 5 employees at their 1 location. See insights on Asgard Therapeutics including office locations, competitors, revenue, financials, executives, subsidiaries and more …See details»
Careers - Asgard Therapeutics
Join us. Asgard Therapeutics is a private biotech company aiming to advance cancer immunotherapies by harnessing direct in-vivo cell fate reprogramming technologies. Formed …See details»
Asgard Therapeutics | BIO-Europe - Informa Connect
Asgard Therapeutics is a private preclinical-stage biotech company pioneering in vivo direct reprogramming for cancer immunotherapy. Since the end of 2021, Asgard is supported by …See details»
Asgard Therapeutics Granted U.S. Patent for Dendritic Cell …
Lund, Sweden – 01 June – Asgard Therapeutics AB (“Asgard”) today announces that the United States Patent and Trademark Office (USPTO) has granted Asgard’s foundational patent …See details»
Asgard Therapeutics Announces Appointment of Three Members …
Lund, Sweden, November 9 th 2022 – Asgard Therapeutics AB (“Asgard”), a private biotech company pioneering in vivo direct reprogramming approaches for cancer immunotherapy, …See details»
Eurostars-funded REPRINT Project Kick-off Meeting - Pereira Lab
For more information: Cristiana Pires, CEO of Asgard Therapeutics, coordinator of the REPRINT project, cristiana.pires@asgardthx.com. In the Photo: In-person kick-off meeting of the …See details»
Asgard Therapeutics Snags €30M to Develop In Vivo Direct Cell ...
LUND, Sweden, March 14, 2024 — Asgard Therapeutics, a privately held biotech company pioneering in vivo direct cell reprogramming for cancer immunotherapy, announces a €30 …See details»
Asgard Therapeutics selects Exothera to bring their viral vector …
For more information, please visit: www.asgardthx.com. About Exothera SA. Exothera is a contract, development, and manufacturing organization (CDMO) dedicated to viral vector and …See details»
Asgard Therapeutics reaches a major research milestone in the ...
Mar 9, 2022 fabio.rosa@asgardthx.com. About Asgard Therapeutics: Asgard Therapeutics is a private biotech company exploring the application of direct cell reprogramming technologies …See details»
Asgard Therapeutics Selects Exothera to Bring their Viral Vector …
Jun 12, 2024 For more information, please visit: www.asgardthx.com About Exothera SA Exothera is a contract, development, and manufacturing organization (CDMO) dedicated to …See details»
News - Asgard Therapeutics
Asgard Therapeutics selects Exothera to bring their viral vector-based immunotherapy candidate AT-108 to clinical trial stage. Asgard Therapeutics today announced it selected Exothera S.A. …See details»